Please assess the completion status of the following clinical trial:

Trial Title: START-J: SiTAgliptin in eldeRly Trial in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with type 2 diabetes who are oral hypoglycemic agent naive or, α-glucosidase inhibitor or biguanide monotherapy (to be washed out 4 weeks prior to randomization)~2. Signed informed consent obtained before any trial-related activities~3. Treatment with diet and exercise for 12 weeks and longer at screening~4. Age =\>60 y.o.~5. Male and Female~6. HbA1c 6.9%=\< \<8.9%~Exclusion Criteria:~1. Active proliferative retinopathy or maculopathy requiring treatment~2. Liver dysfunction (\>x2 of upper normal limit), moderate or severe renal dysfunction(serum Cr\>1.5mg/dL in male, Cr\>1.3mg/dL in female, eGFR\<30), severe cardiac disease (NYHA III or IV), malignancy or uncontrolled hypertension (treated or untreated) as judged by the Investigator~3. Mental incapacity (including moderate or severe dementia) precluding adequate understanding and/or cooperation as judged by the Investigator~4. Recurrent hypoglycaemia or hypoglycaemic unawareness as judged by the investigator~5. Previous history of severe allergy to pharmaceutical products~6. Systemic glucocorticoids users or potential users~7. Suspected type 1 diabetes (including slowly progressive insulin dependent diabetes mellitus) or positive anti-glutamic acid decarboxylase antibody~8. Any condition that the investigator considers a potential obstacle to trial participation and/or data analysis

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): None
- Glimepiride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).